TALWIN SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

PENTAZOCINE (PENTAZOCINE LACTATE)

Inapatikana kutoka:

PFIZER CANADA ULC

ATC kanuni:

N02AD01

INN (Jina la Kimataifa):

PENTAZOCINE

Kipimo:

30MG

Dawa fomu:

SOLUTION

Tungo:

PENTAZOCINE (PENTAZOCINE LACTATE) 30MG

Njia ya uendeshaji:

INTRAMUSCULAR

Vitengo katika mfuko:

1ML

Dawa ya aina:

Narcotic (CDSA I)

Eneo la matibabu:

OPIATE PARTIAL AGONISTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0108852001; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2019-11-21

Tabia za bidhaa

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
TALWIN
(Pentazocine Lactate Injection, USP)
30 mg/mL
Sterile Solution
Narcotic Analgesic
Pfizer Canada Inc.
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Submission Control No.: 213124
Date of Revision:
April 17, 2018
_Product Monograph _
_N_
_Talwin _
_Page 2 of 30 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
................................................................................22
PHARMACEUTICAL INFORMATION
..........................................................................22
PATIENT MEDICATION INFORMATION
...............................